Dermatofibrosarcoma - 38 Studies Found
Completed |
: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma :
|
Completed |
: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma :
|
Completed |
: Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma :
|
Completed |
: Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate : Cancer : 2010-01-11 :
|
Terminated |
: Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma : Sarcoma : 2008-08-22 :
|
Completed |
: Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas :
: Drug: sunitinib malate |
Withdrawn |
: Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma :
: 2006-06-07 :
|
Withdrawn |
: Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma :
: 2006-06-07 :
|
Completed |
: Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases : Life Threatening Diseases : 2005-09-09 : Drug: Imatinib mesylate |
Completed |
: Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans : Dermatofibrosarcoma Protuberans : 2005-10-20 : Drug: imatinib mesylate 400 mg orally twice a day for 10 - 14 days |